
    
      Totally 1600 healthy women of 18-25 years of age were enrolled. The participants were
      randomly stratified into 4 groups and receive different dosage of human papillomavirus (HPV)
      vaccine or placebo administered intramuscularly according to a 0-1-6 month schedule. The
      women were actively monitored for adverse events for 1 month after each injection. Severe
      adverse events during the trial were followed up. Serum samples from all the subjects would
      be collected on day 0, 7m, 24m, 48m and 72m to evaluate the immunogenicity and
      immuno-persistency.
    
  